Financial Performance - The company's operating revenue for 2024 reached ¥2,677,320,710.76, representing a 39.27% increase compared to ¥1,922,348,169.84 in 2023[19]. - The net profit attributable to shareholders for 2024 was ¥820,195,432.44, an 87.91% increase from ¥436,492,212.29 in 2023[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥779,044,218.02, up 90.46% from ¥409,043,029.02 in 2023[19]. - The company's cash flow from operating activities for 2024 was ¥1,050,988,421.40, a 14.64% increase from ¥916,743,866.89 in 2023[19]. - The basic earnings per share for 2024 was ¥1.05, reflecting a 90.91% increase compared to ¥0.55 in 2023[19]. - The total assets at the end of 2024 were ¥5,383,449,076.46, a decrease of 2.88% from ¥5,543,301,641.00 at the end of 2023[19]. - The net assets attributable to shareholders at the end of 2024 were ¥3,333,906,225.54, an increase of 5.92% from ¥3,147,475,025.76 at the end of 2023[19]. - The overall gross margin for the reporting period was 80.78%, with a gross margin of 85.01% for blood perfusion products, indicating strong profitability and market competitiveness[62]. - The company reported a total of ¥4,325,000,000.00 in new purchases of trading financial assets during the reporting period[119]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 8.00 RMB per 10 shares (including tax) to all shareholders based on the total share capital as of the record date for the 2024 profit distribution plan[5]. - The company completed a share repurchase of ¥5 billion, with a cumulative dividend payout since its IPO amounting to ¥34.51 billion, which is 2.45 times the amount raised during the IPO and refinancing[89]. - The company plans to distribute a cash dividend of 620 million RMB for 2024, with a proposed payout ratio exceeding 75%[149]. - The company issued a cash dividend of 310 million RMB for the 2023 fiscal year, with a payout ratio of 70%[149]. - The total cash dividend amount, including other methods, reached 1,119,383,525.57 RMB, representing 100% of the distributable profit[200]. Research and Development - R&D investment for the reporting period was 240 million yuan, accounting for 8.97% of total revenue, with 28 registered medical device products, 25 of which are Class III[54]. - The company employs 486 R&D personnel, representing 17.38% of total employees, with over 30% holding postgraduate degrees[53]. - The company has received 27 authorized patents during the reporting period, including 17 invention patents, bringing the total to 373 authorized patents[84]. - The company is focused on continuous innovation in medical devices, particularly in the field of blood purification and renal therapy[110]. - The R&D strategy includes launching new products, with a focus on blood purification consumables and devices, while improving existing product performance[134]. Market and Product Development - The global medical device market size in 2023 was $582.6 billion, with a year-on-year growth of 9.35%, and is expected to reach $617.6 billion in 2024[29]. - The Chinese medical device market size in 2023 was ¥1,032.8 billion, with a year-on-year growth of 7.79%, and is projected to reach ¥1,110.3 billion in 2024[29]. - The company specializes in the research, development, production, and sales of high-tech medical devices, focusing on innovative blood purification products for various critical conditions[40]. - The company has developed disposable blood perfusion devices for various diseases, including HA series, KHA series, and pHA series for chronic kidney disease patients, addressing individual treatment needs[41]. - The company has established partnerships with over 80 large hospitals for clinical application research, enhancing its market presence[53]. Operational Efficiency and Management - The company has implemented automation and AI technologies in its production processes, improving efficiency and product quality[57]. - The company has initiated a comprehensive digital infrastructure upgrade to enhance operational efficiency and integrate technology with business processes[87]. - The company has a complete organizational structure, including a shareholders' meeting, board of directors, and supervisory board, ensuring effective corporate governance[167]. - The company has established a complete and independent financial department with a standardized financial accounting system, ensuring independent financial decision-making[167]. - The company has a robust internal management structure that operates independently from its controlling shareholders[167]. Social Responsibility and Compliance - The company donated cash and materials valued at ¥38.3 million for various social responsibility initiatives, including charity and public health projects[92]. - The company actively engages with stakeholders and fulfills social responsibilities in areas such as environmental protection and public welfare[165]. - The company has committed to enhancing legal compliance training for its directors and related personnel following a trading incident[183]. - The company strictly adheres to information disclosure regulations, ensuring timely and accurate communication with investors[163]. Future Outlook and Strategic Goals - The company will continue to focus on the blood purification field and expand into international markets, targeting chronic diseases such as uremia and liver disease[133]. - The company aims to enhance its product line and technical strength through mergers and acquisitions, leveraging capital market tools[133]. - The company plans to establish suitable production bases to ensure capacity and enhance manufacturing capabilities through smart manufacturing[134]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of $30 million allocated for potential mergers[176]. - The company has a clear strategy for independent operations, ensuring no overlap with the interests of its controlling shareholders[167].

健帆生物（300529）公告，2024年营业收入26.77亿元，同比增长39.27%。归属于上市公司股东的净利 润8.2亿元，同比增长87.91%。基本每股收益1.05元/股，同比增长90.91%。公司拟向全体股东每10股派 发现金红利8元(含税)，送红股0股(含税)，以资本公积金向全体股东每10股转增0股。 ...

4月15日，健帆生物今日收盘24.39元，下跌1.26%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到24.21倍，总市值194.78亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均46.44倍，行业中值30.39倍，健帆生物排 名第59位。 截至2024年三季报，共有415家机构持仓健帆生物，其中基金415家，合计持股数10103.07万股，持股市 值29.64亿元。 健帆生物科技集团股份有限公司主要从事生物材料和高科技医疗器械的研发、生产及销售。主要产品有 血液灌流器、血液净化设备、血液透析粉液产品。公司先后获评为国家火炬计划重点高新技术企业、国 家制造业单项冠军示范企业、国家技术创新示范企业、国家知识产权示范企业。荣获国家科技进步二等 奖、广东省科学技术进步一等奖。 最新一期业绩显示，2024年三季报，公司实现营业收入21.96亿元，同比47.76%；净利润7.92亿元，同 比86.86%，销售毛利率81.31%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)59健帆生物24.2144.626.14194.78亿行业平均 46.4449.384.75102.60亿 ...

Core Viewpoint - The announcement provides an update on the conversion of the company's convertible bonds, specifically the "Jianfan Convertible Bonds," detailing the current conversion price and the status of the bonds as of the first quarter of 2025 [1][7]. Group 1: Convertible Bond Issuance and Listing - The company issued 10 million convertible bonds with a total value of 1 billion RMB, each with a face value of 100 RMB, approved by the China Securities Regulatory Commission on June 23, 2021 [1][2]. - The bonds were listed on the Shenzhen Stock Exchange on July 21, 2021, under the name "Jianfan Convertible Bonds" and code "123117" [2]. Group 2: Conversion Price Adjustments - The initial conversion price was set at 90.60 RMB per share, which was adjusted to 90.57 RMB due to an increase in total share capital from stock options and restricted stock grants [2][3]. - Further adjustments were made, with the conversion price changing to 89.68 RMB after a cash dividend distribution and later to 89.51 RMB due to additional stock options and share repurchases [3][4]. - As of April 24, 2023, the conversion price was significantly reduced to 62.38 RMB, and subsequently adjusted to 61.72 RMB after another dividend distribution [4][5]. Group 3: Current Status of Convertible Bonds - As of the first quarter of 2025, the latest effective conversion price is 39.43 RMB per share, with 9,998,419 bonds remaining and a total face value of 999,841,900 RMB [7][8]. - There were no conversions of the bonds during the first quarter of 2025, resulting in no impact on the company's share capital structure [8].

证券代码：300529 证券简称：健帆生物 公告编号：2025-012 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于 2025 年第一季度健帆转债转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 （一）可转换公司债券发行情况 经中国证券监督管理委员会"证监许可[2020]3617 号"文同意注册，健帆生 物科技集团股份有限公司于 2021 年 6 月 23 日向不特定对象发行了 1,000.00 万 张可转换公司债券，每张面值 100 元，发行总额人民币 100,000.00 万元。本次向 不特定对象发行的可转债向公司在股权登记日收市后登记在册的原股东优先配 售，原股东优先配售后余额部分（含原股东放弃优先配售部分）采用网上向社会 公众投资者通过深交所交易系统发售的方式进行。对认购金额不足 100,000.00 万 元的部分由主承销商包销。 1 1、 健帆转债（债券代码：123117）的转股期限为 2021 年 12 月 29 日至 2027 年 6 月 22 日，最新有效的转股价格为 39.43 元/股。 2、 ...

证券代码：300529 证券简称：健帆生物 公告编号：2025-011 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于公司产品获得欧盟 MDR 认证的公告 二、医疗器械基本情况 本次取得欧盟 MDR 认证的产品为公司 Future F20 血液净化设备。Future F20 血液净化设备可以支持血液灌流（HP）、血浆吸附（PA）和双重血浆分子吸附 （DPMAS，即人工肝技术）等血液吸附治疗模式，能与公司血液灌流器和血浆 胆红素吸附器等血液净化耗材产品配合使用，为医护和患者提供更优质的血液吸 附治疗服务。 三、对公司的影响 Medical Devices Regulation（EU）2017/745（MDR）是欧盟最新医疗器械法 1 1. 证书名称：EU Quality Management System Certificate (MDR) 2. 认证产品：Future F20 Hemoadsorption Equipment 3. 制造商：健帆生物科技集团股份有限公司 4. 注册证号：G15 103949 0008 Rev. 00 5. 产品分类：IIb 6. 证书签批时间：2 ...

证券代码：300529 证券简称：健帆生物 公告编号：2025-010 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于不向下修正健帆转债转股价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 （二）可转债上市情况 经深交所同意，公司 100,000.00 万元可转换公司债券于 2021 年 7 月 21 日起 在深交所挂牌交易，债券简称"健帆转债"，债券代码"123117"。 1 （三）可转债转股期限 根据《深圳证券交易所创业板股票上市规则》等相关规定和《健帆生物科技 集团股份有限公司创业板向不特定对象发行可转换公司债券募集说明书》（以下 简称"《募集说明书》"）的有关约定，本次可转换公司债券转股期限自发行结 束之日（2021 年 6 月 29 日）满六个月后的第一个交易日起至可转换公司债券到 期之日止，即 2021 年 12 月 29 日至 2027 年 6 月 22 日。 （四）可转债转股价格调整情况 特别提示： 2025 年 2 月 25 日，健帆生物科技集团股份有限公司（以下简称"公司"） 召开第五届董事会第二十 ...

| 证券代码：300529 | 证券简称：健帆生物 | 公告编号：2025-009 | | --- | --- | --- | | 债券代码：123117 | 债券简称：健帆转债 | | 健帆生物科技集团股份有限公司 第五届董事会第二十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 健帆生物科技集团股份有限公司（以下简称"公司"）第五届董事会第二十 六次会议于 2025 年 2 月 25 日在公司会议室以现场会议及通讯表决的方式召开， 本次会议应出席董事 9 人，实际出席董事 9 人，符合《公司法》和《公司章程》 的有关规定。本次会议通知提前以电子邮件及电话通知等方式向全体董事送达。 公司董事长董凡先生召集和主持了本次会议，公司部分监事和高级管理人员列席 了会议。本次董事会的召开符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 经与会董事认真讨论，审议并表决通过了以下议案： 1、审议通过了《关于不向下修正健帆转债转股价格的议案》 公司董事董凡、唐先敏、廖雪云为"健帆转债"持有人，董事雷雯系董凡之 配偶， ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、证券代码：300529 证券简称：健帆生物 2、债券代码：123117 债券简称：健帆转债 3、转股价格：39.43 元/股 证券代码：300529 证券简称：健帆生物 公告编号：2025-008 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于预计触发转股价格向下修正条件的提示性公告 4、转股期限：2021 年 12 月 29 日至 2027 年 6 月 22 日 5、根据公司《健帆生物科技集团股份有限公司创业板向不特定对象发行可 转换公司债券募集说明书》（以下简称"《募集说明书》"）规定：在可转债存 续期间，当公司股票在任意连续三十个交易日中至少有十五个交易日的收盘价格 低于当期转股价格的 85%时，公司董事会有权提出转股价格向下修正方案并提 交公司股东大会表决。 自 2025 年 2 月 5 日至 2025 年 2 月 18 日，公司股票已有十个交易日低于当 期转股价格的 85%。若触发转股价格修正条件，公司将按照《募集说明书》的约 定及时履行后续审议程序和信息 ...

Financial Projections - The expected operating revenue for 2024 is projected to be between 278,700,000 and 259,500,000 CNY, representing a year-on-year growth of 35% to 45% compared to 192,234,820 CNY in the previous year[3]. - The net profit attributable to shareholders is expected to be between 80,000,000 and 86,000,000 CNY, indicating a significant increase of 83% to 97% from 43,649,220 CNY in the same period last year[3]. - The net profit after deducting non-recurring gains and losses is anticipated to be between 74,520,000 and 80,520,000 CNY, reflecting a growth of 82% to 97% compared to 40,904,300 CNY in the previous year[3]. - Non-recurring gains and losses for 2024 are estimated to impact net profit by approximately 5,480,000 CNY, primarily from government subsidies and investment income, compared to 2,744,920 CNY in 2023[6]. Business Performance - The company has experienced favorable external policy conditions and has leveraged its technological and market advantages in blood perfusion, leading to strong business growth in nephrology, hepatology, and critical care[5]. - The company has implemented cost reduction measures, resulting in a decrease in the expense ratio, contributing to the substantial increase in net profit[5]. Financial Reporting - The financial data presented is based on preliminary estimates by the company's finance department and has not yet been audited by external auditors[4]. - The detailed financial data will be disclosed in the 2024 annual report, and investors are advised to make cautious decisions and be aware of investment risks[7].